C3 and lobular neoplasia: In lupus nephritis (LN), anti-dsDNA antibodies and complement C3/C4 levels are key indicators. However, approximately 20–30% of patients lack characteristic antibody titre fluctuations, complicating active lesion surveillance (20, 21).